About Us
Management
ImmunoChemistry Technologies, LLC (ICT) is a biotechnology company based in Bloomington, Minnesota, USA. ICT is a limited liability company (LLC) and is owned and managed by four partners:
- Gary L. Johnson, President
- Dr. Brian W. Lee, Vice President of R&D
- Sally Hed, Vice President of Marketing & Operations
- Carol Lee, Board Member
History
ICT was founded in 1994 and financed by the owners. Since then, ICT has grown into a profitable business with many employees. ICT started as contract laboratory focusing on custom immunoassay development services and selling ELISA products. In 1999, ICT expanded its product lines by developing detection reagents for cell death and related areas of basic research. Today we have over 30 distributors selling our products worldwide. From 2008-2010, ICT was awarded almost $2 million from the NIH for four grant projects to develop in vivo tracer biomarker reagents. ICT has also established several key collaborations with academic and corporate partners to further develop its in-house technology for in vivo detection. In 2010, ICT reinvested over half of its income into R&D.
Products, Services, & Research
ICT is one of the world's leading suppliers of unique in vivo and in vitro detection tools critical for discovering promising investigational medicines. ICT's fluorescent detection probes are used to assess apoptosis and cell death in cultured cells and living animals. ICT's specialty in vitro probes detect active caspases, cathepsins, serine proteases, cholinesterase enzymes, and assess mitochondrial health. ICT’s proprietary FLIVO probes are used in vivo to assess apoptosis in living animal research models.
FLIVO may be used to assess the efficacy of chemotherapy, to quantify neurodegeneration, and as an early detector of eye disease, among other applications. It may eventually be used to better manage disease and personalize treatment. 
FLIVO won LifeScience Alley's New Technology Showcase Award in Dec. 2008.
ICT's contract laboratory specializes in custom ELISA development, manufacturing, and testing services. As an out-growth of these services, ICT offers a specialty line of ELISA buffers and stabilizers for assay development and manufacturing.
Location
ImmunoChemistry Technologies, LLC
9401 James Avenue South, Suite 155
Bloomington, MN 55431 U.S.A.
Phone: 800-829-3194 and 952-888-8788
Fax: 952-888-8988
Contact Us
Customer Service:
Telephone: 952-888-8788
Fax: 952-888-8988
Email: sales@immunochemistry.com
Order: www.immunochemistry.com/products
Gary Johnson, President
Gary Johnson co-founded ICT in 1994 and has acted as its President ever since. His responsibilities include business development, strategic planning, budget administration, preparation of proposals, and contract negotiations. Previous to starting ICT, Mr. Johnson held many managerial and scientific positions. He was a conjugation chemist at R&D Systems; he supervised the ELISA development group at Solvay Animal Heath; he developed assays for infectious diseases and allergies at 3M Biosciences Lab; and he was a research scientist studying the difference between diabetic and non-diabetic glomerular basement membrane proteoglycans in kidney disease at the University of Minnesota, among other projects. Mr. Johnson earned a BS in Microbiology from the University of Minnesota in 1977.
Dr. Brian W. Lee, Vice President of R&D
Dr. Brian Lee co-founded ICT in 1994 and has acted as its Vice President of Research & Development ever since. His responsibilities include the development of new products, managing contract ELISA development projects, and overseeing production. Previous to starting ICT, Dr. Lee developed ELISAs at R&D Systems and Surmodics. In 1992, Dr. Lee earned a PhD from the University of Minnesota, Department of Veterinary PathoBiology.
Sally Hed, Vice President of Marketing & Operations
Sally Hed joined ICT in 1996 as a scientist and was made Vice President of Marketing and Operations and co-owner in 1998. Her responsibilities include sales and marketing, human resources, financial management, strategic planning, and quality control. Previous to joining ICT, Ms. Hed worked as a laboratory assoociate at R&D Systems developing ELISAs. Ms. Hed earned a BS in Genetics and Cell Biology from the University of Minnesota in 1991, and a MBA from Cardinal Stritch University in 1999.
Learn more about ICT by visiting us on Facebook.
